- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03658538
Motivational Interviewing and Air Cleaners for Smokers With COPD (MOVE COPD) (MOVE-COPD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
People with COPD who have higher exposure to indoor pollutants, including particulate matter (PM), second hand smoke (SHS), and nitrogen dioxide (NO2) have worse respiratory morbidity including a higher risk of exacerbations. These effects are not obscured by smoking habit. Unfortunately, despite the clear detrimental impact of poor air quality on respiratory outcomes, regardless of smoking status, to investigators' knowledge, there are no studied environmental interventions targeting indoor air quality to improve respiratory health of smokers, thus ignoring a potential target for harm reduction.
Investigators propose a randomized controlled intervention trial to test whether targeted reductions of multiple indoor pollutants (PM, SHS and NO2) in homes of smokers with COPD will improve respiratory outcomes. Investigators have chosen a potent, multimodal intervention in order to maximize the opportunity to prove that there is a health benefit to active smokers with COPD from indoor air pollution reduction. After a one-month run in period in which all participants will receive smoking cessation strategies including Motivational Interviewing (MI) and nicotine replacement therapy, participants unable to quit smoking (n=120) will have 1:1 randomization to receive either 1) multi-component environmental intervention (active "high-efficiency particulate air"(HEPA) air cleaners + MI intervention for SHS reduction) or 2) sham air cleaners. Referrals to community resources for additional support will also be provided. Investigators aim to determine whether a multi-component environmental intervention (targeting PM, SHS and NO2 reduction) will improve respiratory morbidity (i.e., symptoms, quality of life, lung function and exacerbation risk) (Specific Aim #1) and intermediate outcome measures (i.e., markers of airway and systemic inflammation and oxidative stress) (Specific Aim #2) in smokers with COPD. Investigators anticipate that results from this study will inform clinical practice guidelines and health care policies aimed at reducing COPD morbidity and may have broader implications for indoor environmental recommendations for smokers with chronic disease.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Wendy Lorizio, MD, MPH
- Phone Number: 4105502449
- Email: wlorizi1@jhmi.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Recruiting
- Johns Hopkins Bayview Campus
-
Contact:
- Maggie Maly
- Phone Number: 410-550-9527
- Email: mmaly1@jhmi.edu
-
Principal Investigator:
- Nadia N Hansel, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 40 years,
- Physician diagnosis of COPD,
- Global Initiative for Obstructive Lung Disease (GOLD) Stage II-IV disease with Forced Expiratory Volume (FEV1)/ Forced Vital Capacity (FVC) <70% and FEV1 (% predicted) <80%. IF FEV1/FVC <70% and FEV1 (% predicted) ≥ 80%, additional requirement will apply/will be asked: CAT score ≥ 10 OR exacerbation history during the last 12 months.
- Tobacco exposure ≥ 10 pack-years
- Current smoker with an exhaled Carbon Monoxide (eCO) ≥ 7 ppm to confirm smoking status. We will employ a combination of self-report and a biochemical marker to identify former-smokers. (If no eCO performed due to COVID-19 pandemic safety reasons, we will rely on self-report smoking status and self-report 7-day abstinence questionnaire answers)
- No home smoking ban. IF smoking is not allowed indoor (inside participant's home) then a "home air quality assessment visit" may be done.
Exclusion Criteria:
- Chronic systemic corticosteroids,
- Other chronic lung disease including asthma,
- Living in location other than home (e.g., long term care facility)
- Home owner or occupant planning to move or change residence within study period.
- Air Cleaners drop off (home visits temporary criteria due to COVID-19).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active Treatment
The active treatment arm will receive two portable active HEPA air cleaners as well as 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).
|
The active treatment arm will receive two active air cleaners with HEPA and carbon filters to support a home smoking ban and SHS reduction.
The active treatment arm will receive 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants). The Control arm will receive only continued counseling for smoking cessation. |
Sham Comparator: Control Arm
Homes in the control group will receive Sham air cleaners that have the internal HEPA filter removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
The control arm will not receive phone based motivational interviewing to support a home smoking ban and SHS reduction, they will receive only smoking cessation counseling.
|
The Control arm will receive sham air cleaners
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in COPD health status
Time Frame: Baseline and 6 months
|
COPD health status will be assessed with the COPD assessment test (CAT).
The total score is from 0 to 40.
Higher scores indicate worse COPD control.
|
Baseline and 6 months
|
Change in Quality of Life
Time Frame: Baseline and 6 months
|
St. George's Respiratory Questionnaire (SGRQ).
The total score is from 0 to 100.
Higher scores indicate more limitations
|
Baseline and 6 months
|
Change in Dyspnea as assessed by the University of California San Diego Shortness of Breath Questionnaire (SDSOBQ)
Time Frame: Baseline and 6 months
|
Dyspnea will be assessed using the University of California San Diego Shortness of Breath Questionnaire (SDSOBQ).
The SDSOBQ scoring will range from 0 to 120 (with higher scores indicating greater difficulty breathing).
|
Baseline and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Dyspnea as assessed by modified medical research Council questionnaire(mMRC)
Time Frame: Change from baseline and 6 months post-randomization
|
Dyspnea will be assessed using the modified medical research Council questionnaire(mMRC).
The total score is from 0 (no dyspnea) to 2 (severe dyspnea).is
from 0 to 40.
Higher scores indicate worse COPD control
|
Change from baseline and 6 months post-randomization
|
Change in aggregate Health Care Utilization (number of episodes reported due to COPD-related exacerbation)
Time Frame: Baseline, 3 month and 6 months post-randomization
|
We will administer a questionnaire to collect participant's self report of Health Care Utilization (HCU) episodes due to COPD-related exacerbation (including need for oral corticosteroids or antibiotics for worsening respiratory symptoms, emergency department (ED) visit or hospitalization).
This questionnaire will be administered at baseline and during the 6 months of follow-up.
Report of HCU due to COPD-related exacerbation will be collected at baseline, at 3 and at 6 month clinic visits.
The aggregate HCU number could range from 0 (zero/none event reported) to 1 or more episodes reported during the last 3 months.
|
Baseline, 3 month and 6 months post-randomization
|
Lung Function as assessed by Forced Expiratory Volume in 1 second (FEV1%)
Time Frame: Baseline and 6 months
|
Pulmonary function testing will be assessed as FEV1% predicted, that is FEV1, adjusted for age, height, race and sex
|
Baseline and 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Systemic markers of inflammation in serum (Interleukin-1 beta)
Time Frame: Baseline and 6 months
|
Interleukin-1 beta concentration in serum (units/mg)
|
Baseline and 6 months
|
Change in Systemic markers of inflammation in serum (C-reactive protein)
Time Frame: Baseline and 6 months
|
C-reactive protein concentration in serum will be expressed in: mg/l
|
Baseline and 6 months
|
Change in Markers of oxidative stress in urine (8-isoprostane)
Time Frame: Baseline and 6 months
|
8-isoprostane concentration in urine (pg/ml)
|
Baseline and 6 months
|
Change in Markers of inflammation in induced sputum (neutrophils count differential)
Time Frame: Baseline and 6 months
|
The induced sputum supernatant will be stored and frozen for comparison on cell count differential (neutrophils)
|
Baseline and 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nadia N Hansel, MD, Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00185955
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD, Chronic Obstructive Pulmonary Disease
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Virginia Commonwealth UniversityFisher and Paykel HealthcareCompletedChronic Obstructive Pulmonary Disease(COPD)United States
-
Reham Mohammed ElmorshedyCompletedChronic Obstructive Pulmonary Disease(COPD)Egypt
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Medtronic BRCUnknownCOPD | COPD Exacerbation
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary Disease (COPD) | COPDUnited Kingdom
-
Rigshospitalet, DenmarkUnknown
-
Elpen Pharmaceutical Co. Inc.Completed
Clinical Trials on Active HEPA Air Cleaner
-
Johns Hopkins UniversityNational Institute of Environmental Health Sciences (NIEHS)CompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedLung Diseases | Asthma
-
Wayne State UniversityNot yet recruitingMild Hypertension | Air Pollution Exposure
-
Massachusetts General HospitalBoston Children's HospitalNot yet recruitingViral Infection
-
AlyatecCompletedAsthma | AllergyFrance
-
University of WashingtonNational Institute of Environmental Health Sciences (NIEHS); National Institute... and other collaboratorsCompleted
-
Intermountain Health Care, Inc.CompletedChronic Obstructive Pulmonary DiseaseUnited States
-
UConn HealthBoston University; Tufts University; National Institute of Environmental Health... and other collaboratorsRecruitingBlood Pressure | Cardiovascular Risk FactorUnited States
-
Johns Hopkins UniversityNational Institute of Environmental Health Sciences (NIEHS)CompletedAsthmaUnited States
-
Henry Ford Health SystemWayne State UniversityRecruiting